2019
DOI: 10.1136/annrheumdis-2019-215386
|View full text |Cite
|
Sign up to set email alerts
|

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Abstract: ObjectivesTo compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).MethodsPatients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was supe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
265
0
10

Year Published

2019
2019
2023
2023

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 238 publications
(279 citation statements)
references
References 21 publications
4
265
0
10
Order By: Relevance
“…3,12 Another difference between the specialties was that treatment with non-TNF inhibitor bDMARDs (such as IL-12/-23 and IL-17 inhibitors) was more common in the dermatology setting, whereas treatment with TNF inhibitors was more common in the rheumatology setting. This may be because IL-12/-23 and IL-17 inhibitors have greater efficacy in the treatment of psoriasis, [13][14][15][16] compared with TNF inhibitors. Closer collaboration between the specialties may allow selection of a treatment regimen targeted to the individual patient's disease, including both joint and skin manifestations.…”
Section: Discussionmentioning
confidence: 99%
“…3,12 Another difference between the specialties was that treatment with non-TNF inhibitor bDMARDs (such as IL-12/-23 and IL-17 inhibitors) was more common in the dermatology setting, whereas treatment with TNF inhibitors was more common in the rheumatology setting. This may be because IL-12/-23 and IL-17 inhibitors have greater efficacy in the treatment of psoriasis, [13][14][15][16] compared with TNF inhibitors. Closer collaboration between the specialties may allow selection of a treatment regimen targeted to the individual patient's disease, including both joint and skin manifestations.…”
Section: Discussionmentioning
confidence: 99%
“…A similar observation with regard to enthesitis index was also observed in the SPIRIT-H2H study that compared IL17 inhibition with ixekizumab to adalimumab: a significantly higher proportion of patients reached a SPARCC enthesitis score equal to zero at week 24 in the ixekizumab group. 57…”
Section: Treatmentmentioning
confidence: 99%
“…As the clinical response to anti-IL-23/IL-17A biologics seems better than that to anti-TNF-α biologics in psoriasis, the IL-23/IL-17A axis likely plays a more crucial role than the TNF-α axis in the development of psoriasis [67][68][69][70][71]. Under the regulation of IL-23p19, IL-17A-producing CD4 + helper T (Th17) cells create a self-amplifying, feed-forward inflammatory response that is markedly augmented in the presence of TNF-α [68,72,73].…”
Section: Introductionmentioning
confidence: 99%